Results 11 to 20 of about 61,173 (287)

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

Journal of Thrombosis and Haemostasis, 2021
Fitusiran, an investigational small interfering RNA therapy, reduces antithrombin production to rebalance hemostasis in people with hemophilia A or B, with or without inhibitors.
K. Pasi, T. Lissitchkov, V. Mamonov, T. Mant, M. Timofeeva, C. Bagot, P. Chowdary, P. Georgiev, L. Gercheva‐Kyuchukova, Kate Madigan, H. Nguyen, Qifeng Yu, B. Mei, C. Benson, M. Ragni   +14 more
semanticscholar   +1 more source

Antithrombin and Its Role in Host Defense and Inflammation

International Journal of Molecular Sciences, 2021
Antithrombin (AT) is a natural anticoagulant that interacts with activated proteases of the coagulation system and with heparan sulfate proteoglycans (HSPG) on the surface of cells.
C. Schlömmer, A. Brandtner, M. Bachler
semanticscholar   +1 more source

The antithrombin activity recovery after substitution therapy is associated with improved 28-day mortality in patients with sepsis-associated disseminated intravascular coagulation

Thrombosis Journal, 2023
Background Disseminated intravascular coagulation (DIC) is a common and critical complication in sepsis. Antithrombin activity, which is considered a biomarker for disease severity, was measured in septic DIC treated with antithrombin concentrates in ...
Toshiaki Iba, Tomoki Tanigawa, Hideo Wada, Jerrold H. Levy   +3 more
doaj   +1 more source

Investigation of the Differences in Antithrombin to Heparin Binding among Antithrombin Budapest 3, Basel, and Padua Mutations by Biochemical and In Silico Methods

Biomolecules, 2021
Antithrombin (AT) is a serine protease inhibitor, its activity is highly accelerated by heparin. Mutations at the heparin-binding region lead to functional defect, type II heparin-binding site (IIHBS) AT deficiency.
Réka Gindele, Krisztina Pénzes-Daku, Gábor Balogh, Judit Kállai, Réka Bogáti, Bálint Bécsi, Ferenc Erdődi, Éva Katona, Zsuzsanna Bereczky   +8 more
doaj   +1 more source

Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO

Critical Care, 2020
During extracorporeal membrane oxygenation (ECMO), a delicate balance is required to titrate systemic anticoagulation to prevent thrombotic complications within the circuit and prevent bleeding in the patient.
Meghan M. Chlebowski, Sirine A Baltagi, M. Carlson, J. Levy, P. Spinella   +4 more
semanticscholar   +1 more source

Anticoagulant and signaling functions of antithrombin

Journal of Thrombosis and Haemostasis, 2020
Antithrombin (AT) is a major plasma glycoprotein of the serpin superfamily that regulates the proteolytic activity of the procoagulant proteases of both intrinsic and extrinsic pathways.
A. Rezaie, H. Giri
semanticscholar   +1 more source

The Interaction of Factor Xa and IXa with Non-Activated Antithrombin in Michaelis Complex: Insights from Enhanced-Sampling Molecular Dynamics Simulations

Biomolecules, 2023
The interaction between coagulation factors Xa and IXa and the activated state of their inhibitor, antithrombin (AT),have been investigated using X-ray diffraction studies. However, only mutagenesis data are available for non-activated AT. Our aim was to
Gábor Balogh, Zsuzsanna Bereczky
doaj   +1 more source

Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH

Journal of Thrombosis and Haemostasis, 2020
Hereditary deficiency of antithrombin, a natural anticoagulant, causes a thrombophilia with a high risk for venous thromboembolism. Guidance for laboratory testing to diagnose antithrombin deficiency include the use of an activity assay for initial ...
E. V. Van Cott, C. Orlando, G. Moore, P. Cooper, P. Meijer, R. Marlar   +5 more
semanticscholar   +1 more source

Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study

Turkish Journal of Hematology, 2021
Objective: The defective interplay between coagulation and inflammation may be the leading cause of intravascular coagulation and organ dysfunction in coronavirus disease-19 (COVID-19) patients.
İlkay Anaklı, Perihan Ergin Özcan, Özlem Polat, Günseli Orhun, Gülçin Hilal Alay, Verda Tuna, Emre Çeliksoy, Mehmet Kılıç, Mutlu Mercan, Achmet Ali, Sevgi Beşışık, Figen Esen   +11 more
doaj   +1 more source

Case report: A case of new mutation in SERPINC1 leading to thrombotic microangiopathy

Frontiers in Genetics, 2023
Introduction: Hereditary antithrombin-III deficiency can significantly increase the risk for thrombosis, which is common in limb deep vein and pulmonary cases. However, thrombotic microangiopathy (TMA) caused by hereditary antithrombin deficiency is rare.
Bing Li, Xiaohui Zhang, Hailin Lv, Xiaoqing Yang, Yanxia Gao, Zhao Hu, Chengjun Ma   +6 more
doaj   +1 more source